Close Menu

NEW YORK – Already an established presence in the breast cancer testing space, Hologic's planned acquisition of Biotheranostics provides an opportunity to further expand its footprint in that market, according to company executives.

Last week, Hologic announced the deal to acquire molecular diagnostics firm Biotheranostics for approximately $230 million.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.